PREVPAC (COPACKAGED) Drug Patent Profile

When do Prevpac (copackaged) patents expire, and what generic alternatives are available?

Prevpac (copackaged) is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in PREVPAC (COPACKAGED) is amoxicillin; clarithromycin; lansoprazole. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; lansoprazole profile page.

Summary for PREVPAC (COPACKAGED)

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PREVPAC (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PREVPAC (COPACKAGED)	amoxicillin; clarithromycin; lansoprazole	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL	050757-001	Dec 2, 1997		DISCN	Yes	No

International Patents for PREVPAC (COPACKAGED)

See the table below for patents covering PREVPAC (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	42554
Australia	4589585
Australia	570130
Bulgaria	60415
Canada	1255314	DERIVES DE 2-(PYRID-2-YL)-METHYLTHIO(OU METHYLSULFINYL)BENZIMIDAZOLE ET LEUR PREPARATION (2-(PYRID-2-YL)-METHYLTHIO(OR METHYLSULFINYL) BENZIMIDAZOLE DERIVATIVES AND THEIR PRODUCTION)

Supplementary Protection Certificates for PREVPAC (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210

Last updated: February 4, 2026

What is the current market landscape for PREVPAC (COPACKAGED)?

PREVPAC (COPACKAGED) combines amoxicillin, clarithromycin, and lansoprazole for treatment of Helicobacter pylori infections. It is marketed primarily in regions focusing on oral combination therapies, such as Europe, North America, and select Asia-Pacific markets.

The global Helicobacter pylori eradication market was valued at approximately USD 7 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030. The demand for fixed-dose combination (FDC) therapies, such as PREVPAC, increases as they improve patient compliance.

Market penetration faces competition from single-entity generics, other combination products, and alternative therapies, with key competitors including Pfizer's (e.g., Prevpac in the U.S.), Takeda, and generic manufacturers.

How do the drug’s fundamentals influence investment valuation?

Regulatory Status and Patents

PREVPAC has received regulatory approval in multiple regions. In the U.S., it is marketed by Otsuka Pharmaceuticals and Lilly, with patent protection expired or nearing expiration in various territories. Patent expiry reduces barriers to generic competition but may prompt markets to favor biosimilar alternatives.

Manufacturing and Supply Chain

Production involves stable supply chains for active pharmaceutical ingredients (APIs). Manufacturing depends on sourcing high-quality APIs from established suppliers. Any disruption may impact product availability and revenues.

Pricing and Reimbursement Policies

Pricing varies by country based on healthcare policies. In the U.S., PREVPAC prices are subject to insurance reimbursement and formulary acceptance. Price erosion due to increased generic competition diminishes profit margins.

Market Penetration and Adoption

Physician prescribing patterns, clinical guidelines, and patient preferences influence sales. Growing awareness of eradication protocols supports demand. However, competition from alternative therapies and resistance development can hinder growth.

Innovation and Pipeline

There is limited pipeline activity for PREVPAC, as it is a combination product. Investment attractiveness depends on the potential development of next-generation, resistance-proof therapies or new indications.

What financial metrics are relevant for evaluating the drug’s investment prospects?

Metric	Approximate Status	Implication
Revenue	USD 300-500 million (globally, 2022)	Significant but facing erosion from generics
Gross Margin	50-65%	Moderate, pressured by pricing competition
R&D Investment	Limited	Low ongoing R&D for this specific product
Patent Expiry	Varies by region; some patents expired or expiring	Increased risk of generic entry
Market Share	Approx. 10-20% within targeted indications	Competitive positioning varies geographically

Revenue Trends

Sales have stabilized in some markets but decline globally, especially where generics enter. Companies often seek to renew marketing exclusivity through new formulations, combination strategies, or label extensions.

Cost Structure

Production costs are largely fixed, involving API procurement, manufacturing, and distribution. Margins diminish with increased generic penetration and price erosion.

What are the key risks and opportunities?

Risks

• Patent expiry reduces exclusivity and facilitates competition from generics.
• Resistance development in Helicobacter pylori strains may require therapy modifications.
• Regulatory shifts can affect approval and reimbursement processes.
• Supply chain vulnerabilities for APIs or packaging materials.

Opportunities

• Market expansion in emerging markets with rising Helicobacter pylori prevalence.
• Development of updated formulations with improved resistance profiles.
• Strategic partnerships to extend patent life or enhance distribution.

Final assessment

Investment in PREVPAC (COPACKAGED) hinges on its ability to maintain market share amid patent expiries and evolving competition. Companies with strategic patent filings, cost management, and regional expansion plans maintain higher valuation potential. Long-term growth prospects depend on innovation beyond the current product portfolio.

Key Takeaways

• PREVPAC is a combination therapy with steady global sales but faces patent expirations and increasing generic competition.
• Its market relies heavily on healthcare policy, reimbursement environment, and clinical guideline acceptance.
• Investment valuation demands analyzing regional patent statuses, pricing pressures, and resistance trends.
• The product’s growth potential depends on developing new formulations or indications and expanding into emerging markets.
• Risks include patent expiry, resistance, and regulatory shifts; opportunities lie in regional expansion and formulation innovation.

FAQs

1. How long is PREVPAC typically protected by patents?
   Patents generally last 10-15 years from filing, but expiry varies by region due to patent term adjustments. Most patents associated with PREVPAC have expired or are nearing expiration, increasing generic competition.

2. What are the main competitors to PREVPAC?
   Prevpac's primary competition includes generic co-formulations of amoxicillin, clarithromycin, and lansoprazole, as well as alternative eradication regimens like sequential therapy and bismuth-based quadruple therapy.

3. How does antibiotic resistance affect PREVPAC sales?
   Resistance to clarithromycin and metronidazole can reduce eradication rates, prompting shifts in treatment guidelines and reducing product demand.

4. Can patent extensions or new formulations preserve market exclusivity?
   Yes, through patent extensions, new formulations, or indications, pharmaceutical companies attempt to delay generic entry and sustain revenues.

5. What are key regions for expansion?
   Emerging markets in Asia-Pacific and Latin America show potential due to high Helicobacter pylori prevalence and increasing healthcare access, offering growth opportunities.

---

Sources:

1. MarketWatch, "Helicobacter Pylori Treatment Market Size, Share & Trends Analysis," 2023.
2. FDA and EMA product databases, 2023.
3. IQVIA, "Global Prescription Drug Sales," 2022.
4. Pharmaceutical technology reports on generic drug entry patterns, 2023.
5. Clinical guidelines on Helicobacter pylori management, 2022.